LSTA Q2 2025 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70,000

Gross Profit

$70,000100.0% margin

Operating Income

-$5M-6954.3% margin

Net Income

-$5M-6655.7% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$239,000

Balance Sheet

Total Assets

$25M

Total Liabilities

$4M

Stockholders' Equity

$21M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70,000	$0	—
Gross Profit	$70,000	$0	—
Operating Income	-$5M	-$6M	+11.9%
Net Income	-$5M	-$5M	+7.6%